Singapore technology company develops new drug to treat rare blood cancer

singapore: Singapore biotech company S.Bio has announced the successful development of a new drug that could treat rare blood cancers, which is expected to officially enter the first phase of clinical trials next yearA patented oral drug, codenamed SB1518, has been successfully developed to treat bone marrow hyperploffdiseases
and certain types of blood cancer, the company announced MondayBone marrow hyperplasiadiseaseis a rare form of blood cancer in which bone marrow cell tissue proliferates abnormally, resulting in excessive red blood cells and platelets, as well as problems with bone marrow fibrosisThe new drug stops the abnormal reproduction and division of cells by interfering with signals that cause abnormal reproduction of bone marrow cellsPreliminary experiments show that the new drug can inhibit bone marrow cell growth and fighttumorin test tubes and living bodiesDrCarlson, president of S.Bio, points out that bone marrow hyperplusediseasespatients lack targeted and long-term treatments, and that the new drug, if developed, will provide a glimmer of hope for these patientsThis is the second major breakthrough in the development of anti-cancer drugs in the past 12 months The first cancer drug developed by a Singapore laboratory was also developed by S.Bio, which began its first phase of clinical trials in June this year SB1518's new anticancer drug is expected to begin the first phase of clinical trials in the first half of next year If the trial is successful, the drug will be on the market in five years The Singapore Economic Development Authority was established in the second Year of the Second OOO in a joint venture with Chiron Corporation, a California biotech company Chiron was acquired last year by Novartis, a Swiss drugmaker